Abstract Number: 1896 • ACR Convergence 2023
Systematic Review and Analysis of Mobile Apps for Rheumatoid Arthritis Using the Mobile Application Rating Scale
Background/Purpose: Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by inflammatory polyarthritis with infrequent extra-articular involvement. The management of RA typically requires frequent clinic…Abstract Number: 2095 • ACR Convergence 2023
Integrated Analysis of Gene Expression and Methylation Identifies Biomarkers Associated with Mode of Action of Upadacitinib Treatment in Rheumatoid Arthritis
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase (JAK) inhibitor, significantly improves the signs and symptoms of RA patients1-3. The present study aims to elucidate the…Abstract Number: 2112 • ACR Convergence 2023
Physical Activity in a Cohort of Patients with Rheumatoid Arthritis
Background/Purpose: Physical activity has numerous benefits for Rheumatoid Arthritis (RA) patients such as reducing symptoms like fatigue and pain and improving physical function. The International…Abstract Number: 2128 • ACR Convergence 2023
Higher Vitamin D Levels Before Methotrexate Start Are Associated with Lower Subsequent Mortality in Rheumatoid Arthritis
Background/Purpose: Vitamin D is an immune-modulating hormone. Low Vitamin D levels have been associated with development of autoimmune disease and higher disease activity in early…Abstract Number: 2144 • ACR Convergence 2023
Pharmacodynamic Effects of Nipocalimab in Patients with Moderate to Severe Active Rheumatoid Arthritis (RA): Results from the Multicenter, Randomized, Double-blinded, Placebo-controlled Phase 2A IRIS-RA Study
Background/Purpose: Nipocalimab is a fully human, immunoglobulin G (IgG) 1 monoclonal antibody that blocks the neonatal crystallizable fragment receptor (FcRn), thereby lowering IgG levels. RA…Abstract Number: 2160 • ACR Convergence 2023
Poly-Refractory Rheumatoid Arthritis: All B/tsDMARD Classes Exhausted – An Uncommon Disease Subset with Distinct Inflammatory and Non-inflammatory Phenotypes
Background/Purpose: We previously reported on difficult to treat Rheumatoid Arthritis (RA) in nearly 1600 patients treated with biologic (b) or target synthetic (ts) DMARDs including…Abstract Number: 2426 • ACR Convergence 2023
The Role of β-catenin in Synovial Lining Fibroblast Differentiation
Background/Purpose: In healthy synovium, lining fibroblasts promote joint health by secreting proteoglycans that lubricate the joint cavity. In rheumatoid arthritis (RA), sublining fibroblasts undergo marked…Abstract Number: 2481 • ACR Convergence 2023
Pre-pregnancy Gene Expression Signatures Among Women with Rheumatoid Arthritis May Represent Predictive Biomarkers for Subsequent Improvement or Worsening During Pregnancy
Background/Purpose: Rheumatoid arthritis (RA) can improve naturally during pregnancy in a substantial proportion of women (50-75%), while it may worsen or remain unchanged in others.…Abstract Number: 2582 • ACR Convergence 2023
Expansion of Circulating HLA-DR+ Peripheral Helper T Cells and CXCR5−CD38+ Mature Naïve B Cells in ACPA-positive Individuals At-risk for and with Classified RA
Background/Purpose: Production of ACPA following T and B cell interactions is a hallmark of ACPA+ RA. Recently identified peripheral helper T (Tph) cells have B…Abstract Number: 0060 • ACR Convergence 2023
Serpin B1 Modulation of Immune Complex-Mediated Neutrophil Activation and NET-formation Requires Its Chymotrypsin-like Inhibitory Activity
Background/Purpose: Autoantibody-antigen complex-driven formation of neutrophil extracellular traps (NETs) is a major contributing factor to the pathophysiology and clinical manifestations of many different autoimmune diseases…Abstract Number: 0158 • ACR Convergence 2023
Analyzing User Log Data to Track Provider Use of an EHR-based Dashboard for Rheumatoid Arthritis Outcomes
Background/Purpose: We developed an electronic health record (EHR)-based patient-facing sidecar dashboard application to display RA outcomes, including disease activity, functional status, and pain scores over…Abstract Number: 0327 • ACR Convergence 2023
Self-management Strategies and Self-efficacy in Patients Living with Inflammatory Arthritis: Findings from a Quality Improvement Project in a Tertiary Centre
Background/Purpose: The 2021 EULAR guidelines on self-management have made recommendations (rec) to aid with the implementation of self-management strategies in inflammatory arthritis (IA) (1). Their…Abstract Number: 0392 • ACR Convergence 2023
Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles
Background/Purpose: Despite the diagnostic contribution of Anti-CCP3.1 (cyclic citrillunated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third…Abstract Number: 0409 • ACR Convergence 2023
Prevalence of Pulmonary Manifestations in Patients with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, and Peripheral Spondyloarthritis
Background/Purpose: Pulmonary impairment is a common, yet poorly understood, extraarticular manifestation in rheumatic diseases, which is often inadequately screened and managed. This can result in…Abstract Number: 0426 • ACR Convergence 2023
The Clinical Efficacy of Switching Therapy Between Biological Agents and JAK Inhibitors in the Patients with Rheumatoid Arthritis
Background/Purpose: Some patients with rheumatoid arthritis (RA) need switching therapy between biologic agents (Bio) and Janus kinase inhibitors (JAKi) when efficacy of Bio or JAKi…
- « Previous Page
- 1
- …
- 59
- 60
- 61
- 62
- 63
- …
- 188
- Next Page »